# SPRY4

## Overview
SPRY4, or sprouty RTK signaling antagonist 4, is a gene that encodes a protein involved in the negative regulation of receptor tyrosine kinase (RTK) signaling pathways. The protein, categorized as a signaling antagonist, plays a crucial role in modulating cellular processes such as proliferation, differentiation, and migration by inhibiting key interactions within the MAPK/ERK pathway (Park2019Suppression; Pan2024Role). SPRY4 is characterized by a conserved cysteine-rich SPRY domain, which is essential for its function in protein-protein interactions and signaling modulation. The gene is expressed in various tissues, including the lungs, kidneys, and adipose tissue, and is particularly significant during embryonic development and organogenesis (Pan2024Role). Clinically, SPRY4 is implicated in several conditions, acting as a tumor suppressor in certain cancers while serving as an adverse prognostic biomarker in others, highlighting its complex role in disease progression and potential as a therapeutic target (Kayser2017Clinical; Pan2024Role).

## Structure
SPRY4 (sprouty RTK signaling antagonist 4) is characterized by the presence of a conserved cysteine-rich SPRY domain, which is essential for its function in regulating receptor tyrosine kinase signaling pathways. This domain is a key structural feature that contributes to the protein's ability to interact with other molecules and modulate signaling processes. The SPRY domain is known for its role in protein-protein interactions, which is critical for the inhibitory function of SPRY4 in cellular signaling.

The protein may undergo post-translational modifications, such as phosphorylation, which can influence its activity and interactions. Phosphorylation is a common regulatory mechanism that can alter the conformation and function of proteins, potentially affecting the signaling pathways in which SPRY4 is involved.

Alternative splicing of the SPRY4 gene can result in different isoforms of the protein. These isoforms may have variations in their structure, which could impact their functional properties and interactions within the cell. The existence of multiple isoforms allows for a diversity of regulatory mechanisms and functional outcomes, depending on the specific cellular context and signaling requirements.

## Function
SPRY4, or sprouty RTK signaling antagonist 4, encodes a protein that functions as a negative feedback inhibitor of receptor tyrosine kinase (RTK) signaling pathways, particularly the MAPK/ERK pathway. This protein is involved in regulating various cellular processes, including proliferation, differentiation, and migration, by inhibiting the RAS-RAF interaction and phosphorylation, which subsequently reduces ERK1/2 protein activity (Park2019Suppression; Pan2024Role). SPRY4 is highly expressed in several tissues, including the lungs, kidneys, and adipose tissue, and is active primarily in the cytoplasm (Pan2024Role).

In healthy human cells, SPRY4 plays a crucial role in embryonic development and organogenesis, influencing the development of limbs, midbrain, and other organs (Pan2024Role). It also regulates cell proliferation by modulating pathways such as the EZH2/MDM2/p53 pathway, inducing cell cycle arrest in the G1-G0 phase (Pan2024Role). SPRY4's involvement in cellular signaling extends to its role in inhibiting tumor cell invasion and metastasis by modulating cell adhesion and extracellular matrix degradation (Pan2024Role). The protein's spatial structure, particularly its carboxy-terminal domain, is significant for its function in inhibiting the MAPK pathway and translocating to the cell membrane (Pan2024Role).

## Clinical Significance
Mutations and alterations in the SPRY4 gene are associated with several diseases and conditions. A specific mutation in SPRY4, involving a serine to tyrosine change at position 241, is linked to Kallmann syndrome, a condition characterized by incomplete pubertal development and anosmia. This mutation results in a hyperactive form of SPRY4, which increases its inhibitory effect on fibroblast growth factor (FGF) signaling, contributing to the syndrome's phenotype by reducing FGF signaling (Stütz2021A).

In cancer, SPRY4 plays a complex role. It acts as a tumor suppressor in various cancers, including non-small cell lung cancer (NSCLC) and acute myeloid leukemia (AML), where its expression is associated with better prognosis and reduced tumor progression (Kayser2017Clinical; Pan2024Role). In contrast, in gastric cancer, high SPRY4 expression is linked to poor prognosis, indicating its role as an adverse prognostic biomarker (Pan2024Role).

Alterations in SPRY4 expression, such as reduced levels in glioblastoma and hepatocellular carcinoma, are associated with increased tumor invasion and resistance to therapies, highlighting its potential as a therapeutic target (Pan2024Role). These findings underscore the clinical significance of SPRY4 in various diseases.

## Interactions
SPRY4 interacts with several proteins, influencing various signaling pathways. It is known to interact with testis protein kinase 1 (TESK1), a dual specificity kinase. This interaction has been confirmed through yeast two-hybrid screens and coimmunoprecipitation assays, suggesting a functional association that is enhanced by growth factor stimulation such as EGF (Leeksma2002Human). SPRY4 also interacts with components of the MAPK/ERK pathway, including GRB2 and SOS1, which are involved in modulating receptor tyrosine kinase signaling (Pan2024Role).

In the context of cancer, SPRY4 has been shown to interact with Mdm2, a protein that regulates focal adhesion formation and metastasis independently of p53. This interaction is crucial for regulating cell migration and metastasis, with SPRY4 playing a role in inhibiting these processes (de2024Mdm2). SPRY4 also binds to Raf1 in the VEGF pathway, inhibiting Ras-independent ERK activation, and interacts with CD82, a migration suppressor, which is associated with reduced MMP-9 activity, a matrix metalloproteinase involved in cancer metastasis (Tennis2010Sprouty4). These interactions highlight SPRY4's role in regulating cellular signaling and its potential impact on cancer progression.


## References


[1. (Leeksma2002Human) Onno C. Leeksma, Tanja A. E. van Achterberg, Yoshikazu Tsumura, Jiro Toshima, Eric Eldering, Wilma G. M. Kroes, Clemens Mellink, Marcel Spaargaren, Kensaku Mizuno, Hans Pannekoek, and Carlie J. M. de Vries. Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase tesk1. European Journal of Biochemistry, 269(10):2546–2556, May 2002. URL: http://dx.doi.org/10.1046/j.1432-1033.2002.02921.x, doi:10.1046/j.1432-1033.2002.02921.x. This article has 71 citations.](https://doi.org/10.1046/j.1432-1033.2002.02921.x)

[2. (Park2019Suppression) Sunghyun Park, Yoshie Arai, Byoung Ju Kim, Alvin Bello, Sajjad Ashraf, Hansoo Park, Kyung-Soon Park, and Soo-Hong Lee. Suppression of spry4 promotes osteogenic differentiation and bone formation of mesenchymal stem cell. Tissue Engineering Part A, 25(23–24):1646–1657, December 2019. URL: http://dx.doi.org/10.1089/ten.tea.2019.0056, doi:10.1089/ten.tea.2019.0056. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1089/ten.tea.2019.0056)

[3. (Stütz2021A) Astrid Stütz, Anna Z. M. Kamptner, and Hedwig Sutterlüty. A sprouty4 mutation identified in kallmann syndrome increases the inhibitory potency of the protein towards fgf and connected processes. International Journal of Molecular Sciences, 22(4):2145, February 2021. URL: http://dx.doi.org/10.3390/ijms22042145, doi:10.3390/ijms22042145. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms22042145)

[4. (de2024Mdm2) Rafaela Muniz de Queiroz, Gizem Efe, Asja Guzman, Naoko Hashimoto, Yusuke Kawashima, Tomoaki Tanaka, Anil K. Rustgi, and Carol Prives. Mdm2 requires sprouty4 to regulate focal adhesion formation and metastasis independent of p53. Nature Communications, August 2024. URL: http://dx.doi.org/10.1038/s41467-024-51488-2, doi:10.1038/s41467-024-51488-2. This article has 0 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-024-51488-2)

[5. (Tennis2010Sprouty4) Meredith A. Tennis, Michelle M. Van Scoyk, Scott V. Freeman, Katherine M. Vandervest, Raphael A. Nemenoff, and Robert A. Winn. Sprouty-4 inhibits transformed cell growth, migration and invasion, and epithelial-mesenchymal transition, and is regulated by wnt7a through pparγ in non–small cell lung cancer. Molecular Cancer Research, 8(6):833–843, June 2010. URL: http://dx.doi.org/10.1158/1541-7786.mcr-09-0400, doi:10.1158/1541-7786.mcr-09-0400. This article has 75 citations and is from a peer-reviewed journal.](https://doi.org/10.1158/1541-7786.mcr-09-0400)

[6. (Kayser2017Clinical) Sabine Kayser, Maximilian Feszler, Julia Krzykalla, Matthias Schick, Michael Kramer, Axel Benner, Felicitas Thol, Uwe Platzbecker, Carsten Müller‐Tidow, Anthony D. Ho, Gerhard Ehninger, Michael Heuser, Richard F. Schlenk, Christian Thiede, Christoph Röllig, and Alwin Krämer. Clinical impact of<scp>kmt</scp>2c and<scp>spry</scp>4 expression levels in intensively treated younger adult acute myeloid leukemia patients. European Journal of Haematology, 99(6):544–552, October 2017. URL: http://dx.doi.org/10.1111/ejh.12972, doi:10.1111/ejh.12972. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/ejh.12972)

[7. (Pan2024Role) Hao Pan, Renjie Xu, and Yong Zhang. Role of spry4 in health and disease. Frontiers in Oncology, April 2024. URL: http://dx.doi.org/10.3389/fonc.2024.1376873, doi:10.3389/fonc.2024.1376873. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2024.1376873)